Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs by Georgi Iskrov et al.
September 2016 | Volume 4 | Article 2141
Original research
published: 30 September 2016
doi: 10.3389/fpubh.2016.00214
Frontiers in Public Health | www.frontiersin.org
Edited by: 
Mirjana Ratko Jovanovic, 
Clinical Center Kragujevac, Serbia
Reviewed by: 
Natasa Djordjevic, 
University of Kragujevac, Serbia  
Martin Dlouhy, 
University of Economics, Prague, 
Czech Republic
*Correspondence:
Georgi Iskrov  
iskrov@raredis.org
Specialty section: 
This article was submitted 
to Health Economics, 
a section of the journal 
Frontiers in Public Health
Received: 15 August 2016
Accepted: 13 September 2016
Published: 30 September 2016
Citation: 
Iskrov G, Miteva-Katrandzhieva T and 
Stefanov R (2016) Multi-Criteria 
Decision Analysis for Assessment 
and Appraisal of Orphan Drugs. 
Front. Public Health 4:214. 
doi: 10.3389/fpubh.2016.00214
Multi-criteria Decision analysis
for assessment and appraisal  
of Orphan Drugs
  
Georgi Iskrov1,2*, Tsonka Miteva-Katrandzhieva1,2 and Rumen Stefanov1,2
1 Department of Social Medicine and Public Health, Faculty of Public Health, Medical University of Plovdiv, Plovdiv, Bulgaria, 
2 Institute for Rare Diseases, Plovdiv, Bulgaria
Background: Limited resources and expanding expectations push all countries and 
types of health systems to adopt new approaches in priority setting and resources 
allocation. Despite best efforts, it is difficult to reconcile all competing interests, and 
trade-offs are inevitable. This is why multi-criteria decision analysis (MCDA) has played 
a major role in recent uptake of value-based reimbursement. MCDA framework enables 
exploration of stakeholders’ preferences, as well as explicit organization of broad range 
of criteria on which real-world decisions are made. Assessment and appraisal of orphan 
drugs tend to be one of the most complicated health technology assessment (HTA) 
tasks. Access to market approved orphan therapies remains an issue. Early constructive 
dialog among rare disease stakeholders and elaboration of orphan drug-tailored decision 
support tools could set the scene for ongoing accumulation of evidence, as well as for 
proper reimbursement decision-making.
Objective: The objective of this study was to create an MCDA value measurement model 
to assess and appraise orphan drugs. This was achieved by exploring the preferences on 
decision criteria’s weights and performance scores through a stakeholder-representative 
survey and a focus group discussion that were both organized in Bulgaria.
results/conclusion: Decision criteria that describe the health technology’s charac-
teristics were unanimously agreed as the most important group of reimbursement con-
siderations. This outcome, combined with the high individual weight of disease severity 
and disease burden criteria, underlined some of the fundamental principles of health 
care – equity and fairness. Our study proved that strength of evidence may be a key 
criterion in orphan drug assessment and appraisal. Evidence is used not only to shape 
reimbursement decision-making but also to lend legitimacy to policies pursued. The 
need for real-world data on orphan drugs was largely stressed. Improved knowledge 
on MCDA feasibility and integration to HTA is of paramount importance, as progress in 
medicine and innovative health technologies should correspond to patient, health-care 
system, and societal values.
Keywords: health technology assessment, reimbursement, decision-making, multi-criteria decision analysis, 
orphan drugs, rare diseases
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inTrODUcTiOn
hTa and reimbursement Decision-Making
Ongoing progress in medicine, sustaining financial burden on 
health-care systems, and increasing demand for public scrutiny 
have made authorities and payers rewrite health policy over the 
last decade. With growing use and importance of health tech-
nology assessment (HTA) in reimbursement decision-making, 
stakeholders are confronted with methodological challenges due 
to specific characteristics of health technologies, their develop-
mental environment, and regulation process (1).
Health technology assessment is defined as a multidisciplinary 
process that summarizes information about the medical, social, 
economic, and ethical issues related to the use of a health tech-
nology in a systematic, transparent, unbiased, robust manner. In 
times of fiscal austerity, HTA has been a particularly appraised 
decision support tool for formulation of safe, effective, health 
policies that are patient focused and seek to achieve best value (2). 
HTA is usually perceived to be weighting clinical and economic 
evidence, combining those considerations into an incremental 
cost-effectiveness ratio (ICER). Theoretically, this outcome 
should define reimbursement decisions. Nevertheless, ICER and 
HTA remain purely technical tools. It is the health authorities that 
make final decisions, taking into account various other factors 
as well. Innovative health technologies complicate this problem 
further. They require additional consideration of context and 
implementation attributes, which go far beyond ICER (3, 4).
Limited resources and expanding expectations push all coun-
tries and all types of health systems to adopt new approaches 
in priority setting and resources allocation. All stakeholders 
understand that decision-making is a complex process. Despite 
best efforts, it is difficult to reconcile all competing interests, and 
trade-offs are inevitable. This explains the recent uptake of value-
based pricing and reimbursement (5). Furthermore, innovation 
in medical research and development requires innovation of the 
HTA process too. HTA should be updated in order to respond 
to such challenges, as innovative health technologies pose new 
critical factors, which affect patients, payers, and providers 
(6). Current HTA methodology presents limitations regard-
ing integration of the diversity of stakeholders’ perspectives in 
reimbursement decisions. Standard health economic tools do not 
allow responding to those concerns. A possible way to address 
this issue would be to have a societal consensus on a collective 
solution for all stakeholders (7). This could be achieved by engag-
ing all groups and reflecting all preferences.
McDa and reimbursement  
Decision-Making
Multi-criteria decision analysis (MCDA) could be a major fac-
tor in this health policy challenge. This methodology represents 
a process of evaluation of alternatives by taking into account 
multiple criteria in an explicit manner. MCDA provides a struc-
tured, transparent approach to identify preferred alternatives 
by means of combined calculation of the relative importance 
of different criteria and the performance of the alternatives on 
these criteria. MCDA framework enables the exploration of 
stakeholders’ preferences, as well as the explicit organization of 
broad range of criteria on which real-world decisions are based. 
MCDA gives insights into the rationale behind value assessment 
and appraisal (5, 8).
Health technology assessment and reimbursement decisions 
are complex due to multiple aspects considered and gaps in 
evidence. However, transparency is not about uniformity of deci-
sions. Transparency means consistency of decisions over time. 
Decision-making framework needs to explain how seemingly 
different appraisals are done by different groups at different times. 
HTA inevitably goes together with limits. Nevertheless, restric-
tions are most accepted when they are transparent and consistent. 
Reimbursement decisions should foster sustainable population 
health by recognizing policy priorities and fiscal constraints while 
giving due weight to the rights and claims of individuals who seek 
health care (9).
reimbursement Decision-Making  
of Orphan Drugs
Innovative therapies present an excellent opportunity for a case 
study of the integration between HTA and MCDA. Assessment 
and appraisal of these medicinal products tend to be one of the 
most complicated HTA tasks. This assumption is particularly 
viable in regard to rare diseases and orphan drugs (10–13). Rare 
diseases represent a unique challenge to health authorities and 
payers, as they are life-threatening or chronically debilitating 
conditions with a low prevalence and a high level of complexity. 
It is estimated that between 5000 and 8000 distinct rare diseases 
affect 27–36 million people in the European Union (EU). Because 
of this magnitude, rare diseases call for special, combined efforts 
to prevent significant morbidity or avoidable premature mortal-
ity and to improve quality of life and socioeconomic potential of 
affected persons (14).
Despite regulatory incentives that have stimulated research 
and development of orphan drugs at a global level, timely access 
to market approved ones remains an issue. There are legitimate 
concerns among stakeholders that access to innovative therapies 
for rare diseases is greatly delayed. Conventional HTA is mainly 
concentrated on ICER, marginalizing all other considerations. 
Value assessment and appraisal of orphan drugs is, however, a 
debate of policy priorities, health system specifics, and societal 
attitudes. HTA bodies and payers need to pursue a multidis-
ciplinary analysis on a range of criteria, ensuring an explicit 
understanding of trade-offs in reimbursement decisions. It is also 
important to address the impact of rarity, as quality of orphan 
drug evidence is not the same as for conventional therapies. Early 
constructive dialog among rare disease stakeholders and elabora-
tion of orphan drug-tailored decision support tools could set the 
scene for ongoing accumulation of evidence, as well as for proper 
and timely value assessment and appraisal (15, 16).
aim of the study
The objective of this study was to create an MCDA value measure-
ment model to assess and appraise orphan drugs. This research 
built upon two previous studies in Bulgaria – one analyzing 
reimbursement decision-making on orphan drugs under current 
TaBle 1 | case studies for the pilot model testing.
rare disorder’s 
characteristics
Orphan drug a Orphan drug B
Prevalence <1 in 10,000  
(ultra rare disorder)
1–5 in 10,000 (rare disorder)
Onset Onset in childhood Mixed onset
Need for carer Strong need for carer  
(severe physical and/or  
mental impairment)
Mild need for carer  
(mild physical impairment,  
no mental impairment)
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HTA legal framework (17) and second identifying important 
criteria that are relevant to local stakeholders (4). Therefore, the 
present study’s aim was achieved by exploring the preferences 
on decision criteria’s weights and performance scores through a 
stakeholder-representative survey and a focus group discussion.
MaTerials anD MeThODs
Design of the Value assessment  
and appraisal Model
Multi-criteria decision analysis process consists of several steps: 
definition and structure of the problem; identification of a set 
of decision criteria; elicitation of decision criteria’s weights and 
performance scores; and final value estimate (7). A number of 
MCDA methodologies are available, with various degrees of 
complexity. We used a simple MCDA linear additive model. 
This methodology was chosen as being of most value to health 
authorities and payers (11). The model calculates an overall value 
combining weighted performance scores for all relevant criteria. 
Value assessment and appraisal took a societal perspective. It was 
initially decided that our MCDA model would be 100-point, with 
100 points being the best possible outcome.
identification of a set of Decision criteria
The initial list of reimbursement decision criteria was made 
through a previous closed-ended survey among four stakeholder 
groups (medical professionals, patient representatives, health 
authorities, and industry representatives), reported elsewhere 
(4). This study yielded 15 criteria to form a tentative optimal 
model for drug reimbursement decision-making. Following a 
cross-comparison with the current legal framework in Bulgaria 
(17), those preliminary criteria were reorganized into three 
categories: health technology’s characteristics (five criteria), 
indicated disorder’s characteristics (two criteria), and public 
health aspects (five criteria). All but two criteria (disease burden 
and budget impact) were qualitative. In order to define different 
performance scores for each of those qualitative criteria, specific 
cases and scenarios were identified from a literature review, with 
a specific focus on existing payer value assessment and appraisal 
frameworks.
elicitation of Decision criteria’s Weights 
and Performance scores
Elicitation of weights and performance scores was done through 
an online survey in January–March, 2015. Questionnaire con-
sisted of 19 questions, grouped into sociodemographic profile, 
weight elicitation, performance score estimation, and additional 
contextual considerations. Participants were provided with defi-
nitions of all criteria and scales used in the survey. In order to 
be validated, the questionnaire was pretested by six participants.
Weight elicitation aimed to catch stakeholder preferences of 
what is most important in reimbursement decision-making and 
which criteria should contribute most to value assessment and 
appraisal. A two-step 100-point weight elicitation technique was 
used. First, respondents were asked to distribute 100 value points 
among the three decision criterion categories. Higher number of 
points meant higher importance and more weight in the overall 
value estimate. Participants had to provide relative weights for 
each criterion category from their individual perspective, but 
in the context of reimbursement decisions in general. Then, 
participants had to distribute 100 value points among the criteria 
of each category. Individual weights of criteria were normalized 
to sum up to the weight of the criterion category that was elicited 
at step one.
Performance score elicitation aimed to understand variations 
on how a health technology is assessed and appraised with regard 
to its outcome for each decision criterion. A similar technique 
was applied. Participants had to evaluate different predefined 
performances for each criterion. Rating scale for performance 
scores ranged from 0 points (worst, least desired outcome) to 
100 points (best, most desired outcome). Final weighted score of 
each performance was calculated as the percent from the normal-
ized weight (in points) of the corresponding criterion.
Pilot Value assessment  
and appraisal Model
The preliminary model based on survey results was piloted 
during a focus group discussion in September, 2015. Authors 
of this paper acted as facilitators. Participants were given the 
survey results in advance. The discussion was structured. At the 
beginning of the meeting, attendees were reminded about the 
study’s aim and nature. They were offered the opportunity to 
revise the list of criteria, weights, and performance scores. Any 
changes if necessary, however, had to be justified and consensu-
ally agreed by all.
Then, in order to test the overall model, participants had to rate 
two case studies of hypothetical orphan drugs. The two medicinal 
therapies were indicated in two hypothetical rare diseases with 
clearly differentiated profiles (Table 1). This approach was under-
taken, as preliminary survey results showed disease severity to be 
the single most important decision criteria.
Within the focus group discussion, stakeholders had to assess 
and appraise both orphan drugs, applying the value measure-
ment model. Ratings for each criterion were discussed and 
consensus performance scores served as a “realistic” assessment 
and appraisal scenario. Cases, when agreement was not reached, 
provided scores for “pessimistic” (lowest total value estimate) 
and “optimistic” (highest total value estimate) scenarios. Aided 
by these six scenarios for the two orphan drugs, participants 
were asked to decide upon a reimbursement recommendation 
threshold.
TaBle 2 | response rate per stakeholder groups.
stakeholder groups survey completed (%) Decline to participate (%) Without response (%) Total
Medical professionals 41 (36.3%) – 72 (63.7%) 113
Patient representatives 31 (57.4%) – 23 (42.6%) 54
Health authorities 32 (56.1%) 4 (7.0%) 21 (36.9%) 57
Industry representatives 39 (47.0%) 7 (8.4%) 37 (44.6%) 83
Total 143 (46.6%) 11 (3.6%) 153 (49.8%) 307
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study Participants
Study participants included four groups of public health stake-
holders from Bulgaria: medical professionals, heading university 
hospital clinics, chairs of rare disease patient organizations, health 
authorities (reimbursement decision-makers, working at the 
macro level), market access and governmental affairs executives 
of pharmaceutical companies. A total of 307 stakeholder repre-
sentatives were contacted by e-mail to participate in the survey 
with an invitation letter describing the study. Participants were 
identified through past or present participation (prior works, 
publications, positions held, etc.) in decision-making on drug 
reimbursement with public funds in Bulgaria. Respondents were 
asked to take their own perspective into account when providing 
the relative importance of decision criteria and appraising differ-
ent performances for achievement of those indicators.
Four representatives of each stakeholder group were invited 
to attend a focus group discussion. These individuals were 
deliberately selected from the survey respondents. They were 
additionally chosen to assure variation with regard to age, sex, 
geography, pathology, and governance type.
Approval by Ethics committee was not required for this 
research. The survey and the focus group discussion were 
sociological from a methodological point of view, with no clinical 
research. No personal data were saved or analyzed.
Data analyses
Weights and performance scores obtained from the survey were 
analyzed using SPSS (version 11.5; SPSS, Inc., Chicago, IL, USA). 
Descriptive statistics were applied. Differences in mean weights 
and performance scores were compared between stakeholder, 
age, and sex groups. As data were not normally distributed, 
chi-square and Kruskal–Wallis tests were applied to determine 
whether variations between the groups were significantly differ-
ent at 0.05 levels.
resUlTs
Participants
In total, 143 participants completed the survey, 46.6% overall 
response rate (Table 2). Medical professionals and industry rep-
resentatives produced the biggest numbers of respondents, while 
response rate was higher in patient and health authority groups. 
Also, 11 participants (3.6%) declined to complete the survey.
Respondents aged 36–45 years constituted the biggest group of 
participants (57 people). Also, 63% of the surveyed were women 
who dominated substantially among medical professionals, 
health authorities, and patient representatives. Mean duration 
of professional experience in the field of public health and/or 
rare diseases was 12.7 ± 9.2 years. Older respondents, medical 
professionals, and patient representatives tended to have a longer 
experience.
relative Weights of Decision  
criterion categories
Survey participants provided highest relative weight to the 
decision criterion category that accounts for the properties of 
the health technology – 44 ±  13 value points out of 100. No 
significant difference was observed among stakeholder groups 
(ZKruskal–Wallis =  4.09, p =  0.252) (Figure  1). Other two decision 
criterion categories received 32  ±  11 (criteria describing the 
indicated disorder) and 24 ± 10 points (criteria accounting for the 
public health considerations), respectively. Again, there was no 
significant difference in these weights among the surveyed groups 
(ZKruskal–Wallis = 5.12, p = 0.163 and ZKruskal–Wallis = 1.55, p = 0.671, 
respectively).
Weights and Performance scores of 
Decision criteria That Describe the health 
Technology’s characteristics
Survey participants considered life-saving as the most important 
decision criterion from this category. This criterion received 
26 ± 12 value points out of 100, followed by health benefits and 
clinical effectiveness. There was a general consensus between 
stakeholders regarding the values of these criteria, except for 
life-saving (Figure  2). In this particular case, health authori-
ties gave a significantly higher weight to this consideration 
(ZKruskal–Wallis = 8.11, p = 0.044). Individual weights of all five crite-
ria were later normalized to sum up to the weight of the criterion 
category (44 points). Final weights of these criteria were: health 
benefits – 10 points, clinical effectiveness – 9 points, life-saving – 
11 points, safety – 8 points, and alternative – 6 points.
Different performance scores for the health benefits criterion 
were defined based on health technology’s impact on life expec-
tancy and quality of life. Cure was the ultimate performance, 
receiving the maximum score of this criterion – 10 points. 
Combination of extending life expectancy and improving quality 
of life was considered next best option, estimated with the same 
amount of points by the stakeholders. Choosing between life 
expectancy and quality of life, improving quality of life received 
7 points, one point more than extending life expectancy. Scores 
for the clinical effectiveness criterion were differentiated through 
achievement of clinical and statistical significance. Combination 
of both options was the best case, getting the maximum 9 points 
for this criterion. Performance of clinical significance was 
FigUre 2 | relative weight of decision criteria that describe the health technology’s characteristics per stakeholder groups.
FigUre 1 | relative weight of decision criterion categories per stakeholder groups.
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preferred over performance of statistical significance – 5 vs. 
2  points, respectively. Life-saving and alternative criteria were 
constructed as dichotomous variables, getting all the points in 
the maximum case and no points at all in the minimum case.
Weights and Performance scores of 
Decision criteria That Describe the 
indicated Disorder’s characteristics
Survey participants gave a slight preference to disease severity 
over disease burden. The disease severity criterion received 
53 ±  14 value points out of 100 for this category. There was a 
general consensus between stakeholders regarding the weights 
of these two criteria (Figure 3). Medical professionals, patient, 
and industry representative considered disease severity more 
important in reimbursement decision-making, while health 
authorities was the only group that rated the two criteria equally. 
Nevertheless, there was no significant overall difference in the 
weight values per surveyed groups. Individual weights of the two 
criteria were normalized to sum up to the weight of the criterion 
category (32 points). Final weights of these criteria were disease 
severity – 17 points and disease burden – 15 points.
Scores for the disease severity criterion were differentiated 
through disease progression and prognosis. Estimated perfor-
mance scores for these scenarios were affected by the study’s focus 
on rare diseases. Stakeholders gave more importance on chronic 
FigUre 3 | relative weight of decision criteria that describe the indicated disorder’s characteristics per stakeholder groups.
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life-threatening conditions than on acute ones – 17 vs. 15 points. 
These results were not unanimous. Overall, medical professionals 
and industry representatives considered chronic life-threatening 
disorders more severe, while health authorities preferred acute 
conditions. The difference in the performance scores per groups 
was significant for both cases (ZKruskal–Wallis = 15.24, p = 0.002 for 
acute disorder and ZKruskal–Wallis = 16.32, p = 0.001 for chronic life-
threatening disorder).
Disease burden was one of the two criteria in the study whose 
performance could be quantified. Raw data were taken from the 
results of an EU-funded project, socioeconomic burden and 
health-related quality of life in rare disease patients in Europe 
(BURQOL-RD). BURQOL-RD had evaluated the socioeconomic 
burden for 10 rare diseases in the EU, including Bulgaria (18, 
19). Our study did, however, include only 8 of those 10 condi-
tions due to small sample size for the other 2. Additionally, we 
defined disease burden as the total sum of direct non-health-care 
costs, productivity loss, and early retirement costs. First quartile, 
median, and third quartile of the mean annual socioeconomic 
costs per patient per rare disease defined the performance cases 
of this criterion, and their scores were proportionally assigned. 
Cases below first quartile (low disease burden) got no points at all, 
while cases above third quartile (high disease burden) received all 
points of the criterion.
Weights and Performance scores of 
Decision criteria That account for the 
Public health considerations
Survey participants considered strength of evidence as the 
most important decision criterion from this category. This 
criterion received 25 ±  10 value points out of 100. On the 
opposite side, budget impact was assessed as the least impor-
tant decision criterion – 16 ±  9 points. While there was no 
significant difference in the weight values of budget impact 
and cost-effectiveness criteria per stakeholder groups, health 
authorities gave lowest points for both health economic cri-
teria (Figure 4). There were two substantial differences in the 
distributed weight values from this decision criterion category. 
Medical professionals rated the evidence criterion significantly 
higher (ZKruskal–Wallis = 9.82, p = 0.020). So did health authori-
ties on the vulnerable groups criterion (ZKruskal–Wallis  =  9.56, 
p = 0.023). Individual values of all 5 criteria were normalized 
to sum up to the weight of the criterion category (24 points) 
– 4 points for budget impact, 5 points for cost-effectiveness, 6 
points for strength of evidence, 5 points for vulnerable groups, 
and 4 points for prevention effect.
The budget impact criterion was constructed similarly to the 
disease burden criterion. Data for drug therapy costs were taken 
from the National Health Insurance Fund (20). First quartile, 
median, and third quartile of the mean annual drug therapy cost 
per patient per rare disease defined the cases of this criterion, 
and their performance scores were proportionally assigned. 
Cases below first quartile (low budget impact) got all the criterion 
weight, while cases above third quartile (high budget impact) 
received no points at all.
Cases for the cost-effectiveness criterion were differentiated 
through ICER. The scenario with more effects and less costs was 
the optimal performance score, receiving all 6 points. Choosing 
between the remaining two cases, stakeholders expressed prefer-
ence for the scenario with more effects and more costs over the 
one with fewer effects and less costs – 4 vs. 1.
Different cases for the strength of evidence criterion were 
defined based on conventional hierarchy of evidence. Randomized 
controlled clinical trials constituted the highest performance 
score (8 points), while cross-sectional studies, case reports, and 
expert opinions got only 1 point each. Vulnerable groups crite-
rion was defined with regard to the patient group that the health 
FigUre 4 | relative weight of decision criteria that account for the public health considerations per stakeholder groups.
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technology is indicated in. Prevention effect was a dichotomous 
variable, getting all the points in the maximum case and no points 
at all in the minimum case.
Pilot Value assessment  
and appraisal Model
A total of 13 stakeholders (3 medical professionals, 4 health 
authority representatives, 3 patient representatives, and 3 industry 
representatives) participated in the focus group discussion. Three 
invitees declined to take part due to busy agenda. Nevertheless, 
they sent overall comments on the model. The meeting lasted 
115 min.
The first half of the discussion focused on the list of criteria, 
weights, and performance scores. MCDA rationale was very 
positively perceived by all participants:
“MCDA gives an opportunity of associative thinking 
and in-depth analysis.” (Health authority representative)
“Innovative health technologies are not usually included 
in basic regulations and health insurance packages. 
Therefore, this issue requires many ad hoc decisions.” 
(Industry representative)
When reviewing weights and performance scores of decision 
criteria that describe the health technology’s characteristics, 
stakeholders debated the use of the alternative criterion in the 
context of rare diseases and lack of etiological treatment for 
those conditions. Patient representatives were adamant that in 
the absence of therapeutically equivalent alternatives, appraisal 
of orphan drugs has to be more implicit, and access of patients 
should be guaranteed. Other stakeholders accepted this rationale. 
Nevertheless, they pointed out that resources were scarce, and 
trade-offs were necessary:
“Health budget is always limited, resources can only 
be re-distributed. Re-directing resources to particular 
patients inevitably deprives others from necessary 
medical services.” (Health authority representative)
There was a similar debate on the definition of the life-saving 
criterion. Stakeholders agreed that this condition is only met by 
emergency medicine health technologies. Overall, weights and 
performance scores of decision criteria that describe the health 
technology’s characteristics were consensually agreed, and no 
changes were made (Figure 5).
No amendments were needed for the weights and scores of 
decision criteria that describe the health-indicated disorder’s 
characteristics. All participants underlined that HTA and 
appraisal had to be put in the context of the disorders that these 
technologies were aimed at. There was no surprise that disease 
severity and disease burden were considered to be the most 
important decision criteria (Figure 5).
Weights and performance scores of decision criteria that 
account for the public health considerations were the most debat-
able part of the focus discussion. Strength of evidence was indeed 
accepted as a very substantial decision criterion. Nevertheless, 
physicians and health authorities took a position that real-world 
data from local settings had to be generated and collected too. 
Industry representatives defended data extrapolation as relevant, 
especially in case of rare diseases where expertise and experience 
were limited. Cost-effectiveness and budget impact were also a 
point of opposing views. Medical professionals, patients, and 
industry shared the opinion that access restrictions on innovative 
therapies had a strong negative impact on rare disease patients’ 
health. Patients went even further calling such decisions dis-
criminatory. Physicians suggested that lack of resources was no 
excuse, and health-care system needed improving allocation of 
funds and spending control:
FigUre 5 | Final weighted performance scores of the McDa assessment and appraisal model for orphan drugs.
8
Iskrov et al. Multi-Criteria Decision Analysis for Orphan Drugs
Frontiers in Public Health | www.frontiersin.org September 2016 | Volume 4 | Article 214
FigUre 6 | realistic McDa assessment scenarios for orphan drugs a and B.
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“I understand the rationale of health authorities that 
they are responsible for the efficiency of the health 
system. But there must be a way that allows patients 
to be treated and new evidence to be generated at the 
same time. Otherwise, it’s a vicious circle.” (Patient 
representative)
“I do not object to the economic justification of these 
restrictions. However, basic medical facts have to be 
taken into account. Such limitations must be consistent 
with the effect of treatment on the patient and should 
not be a financial goal solely.” (Medical professional)
The four representatives of health authorities involved in the 
discussion accepted those medical and ethical considerations but 
reminded that resources were limited and health-care system 
had to respond to growing health needs. The only change in the 
weights and performance scores of decision criteria that account 
for the public health considerations concerned the prevention 
effect criterion. Participants agreed that such a consideration was 
not applicable in this context. Furthermore, a health authority 
representative said that prevention effect was partially reflected 
by the criterion of health benefits. So, all stakeholders agreed to 
remove this decision criterion from the final MCDA value model 
and to transfer its weighting points to the other criteria from the 
same category (Figure 5).
The second half of the focus group discussion aimed to test 
the pilot model, as well as to decide upon a reimbursement 
recommendation threshold. Being acknowledged with the value 
assessment and appraisal model, as well as with the two hypo-
thetical drugs, participants had to rate them. Overall, orphan 
drug B got higher scores than orphan drug A. This difference was, 
however, relatively small under the optimistic and pessimistic 
scenarios  –  91 vs. 85 points and 52 vs. 44 points, respectively. 
This gap grew significantly in case of the realistic scenario, the 
most likely expected outcome of the assessment and appraisal 
process – 70 vs. 57 points (Figure 6).
Rarity, namely ultra rarity in case of orphan drug A, was a 
strong predictor of the final value estimate. If health benefits, life-
saving, safety, and alternative criteria had similar performance 
scores in both drugs, the clinical effectiveness criterion achieved 
only 2 points in the realistic scenario for drug A against 5 points 
TaBle 3 | appraisal of the McDa results.
result recommendation support tools
≥70 points (≥70%) Unconditional reimbursement 
with public funds
Epidemiological registries
≥50 points (≥50%) Conditional reimbursement  
with public funds
Epidemiological registries,  
risk-sharing agreements
<50 points (<50%) No reimbursement  
with public funds
Individual access schemes
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for drug B. Achieving clinical and statistical significance is 
considerably more difficult in ultra rare diseases, where the small 
number of patients makes it very hard to collect and analyze 
aggregated data. Although it was discussable to compare which 
of the two types of diseases – rare or ultra rare – would have a 
greater socioeconomic burden, participants shared the view that 
rare diseases, affecting both pediatric and adult cohorts, would 
have a bigger burden, given the loss or reduced productivity of 
both patient and main caregiver. In case of ultra rare pediatric 
disorder with low survival, these indirect costs would be lower. 
Public health considerations contributed for the final difference 
in values too – 18 vs. 13 points for drug B. The advantage for 
medicine B came almost entirely from the criterion of evidence 
strength – 8 vs. 3 points, taking into account the difficulty of 
conducting large-scale clinical trials in ultra rare diseases. As 
expected, budget impact was one of the few criteria, where orphan 
drug A dominated orphan drug B – smaller budget impact given 
the very small number of patients anticipated.
There was a wide range of proposals when discussing the 
threshold for a positive reimbursement decision. There was even 
a suggestion for a “floating” threshold depending on the allocated 
annual resources. Finally, stakeholders agreed on 70 or more 
points as a threshold for a positive recommendation (Table 3). 
In this context, a health technology that is rated between 50 and 
70 points should be recommended for conditional reimburse-
ment. As for health technologies receiving less than 50 points, 
participants backed the idea that this should not mean automatic 
rejection. Instead, industry could make concessions to ensure 
individual access schemes for rare disease patients.
DiscUssiOn
Key Decision criteria Preferences  
in assessment and appraisal of  
Orphan Drugs
Our study identified current perspectives on reimbursement 
decision-making in Bulgaria, as well as differences in stakehold-
ers’ opinions. The methodological approach we applied allowed 
collection and analysis of what matters most in HTA. In a more 
specific context, this mixed-method research helped to under-
stand variations on how orphan drugs are assessed and appraised 
with regard to their outcome for each decision criterion. Improved 
knowledge on MCDA feasibility and integration to HTA is of 
paramount importance, as progress in medicine and innovative 
health technologies should correspond to patient, health-care 
system, and societal values.
Decision criteria that describe the health technology’s charac-
teristics were unanimously agreed as the most important group 
of reimbursement considerations. This outcome, combined 
with the high individual weight of disease severity and disease 
burden, underlined some of the fundamental principles of health 
care – equity and fairness. In this context, disease severity and 
disease burden are especially important decision criteria when 
their level is high. Reimbursement decisions should help relieve 
suffering in those who are worst off. There is increasing awareness 
that valuations of quality-adjusted life-years (QALYs) may differ 
when the QALYs accrue to different patients. Although these 
criteria are substantial in drug reimbursement decision-making, 
health authorities generally struggle in explicitly specifying the 
actual role and weight of disease severity and disease burden 
(21–23). Addressing this issue, Stolk et al. gave a valuable insight 
by describing the proportional shortfall approach that it used to 
operationalize disease severity in the Netherlands. Proportional 
shortfall concentrates on the fraction of QALYs that people lose 
relative to their remaining life expectancy, and not on the absolute 
number of QALYs lost or gained. So, it is the ratio of QALYs 
lost over the QALYs remaining (24). This is one possible equity 
adjustment to the standard cost-effectiveness criteria.
The economic criteria – cost-effectiveness and budget 
impact – turned out to be of lower importance for all stakeholders. 
Health authority representatives who are nominally responsible 
for the health-care system’s sustainability gave lowest weights to 
those criteria (although these variations were not statistically 
significant). Despite being a fundamental part of HTA, those 
considerations have been blamed for restricting patient access to 
treatment (11, 15). Cost-effectiveness is a leading indicator in pri-
ority setting and resource allocation. Meeting this criterion is the 
most important objective from a health economic perspective. In 
practice, however, not only orphan drugs but also very few inno-
vative health technologies tend to be cost-effective. While various 
thresholds for ICER have been discussed, the application of this 
criterion remains a politically and morally dividing issue. ICER 
offers indeed a range of advantages, including reduced burden 
on decision-makers and consistency of decisions. Nevertheless, 
strict application of cost-effectiveness limits the possibility for 
flexibility and inclusion of ad  hoc considerations in HTA (25). 
Moreover, explicit focus on ICER has been pointed out for mar-
ginalizing other important criteria, as well as for limiting patient 
choice and health-care rationing (26).
The budget impact criterion in reimbursement decisions 
has been similarly criticized. While economic analysis allows 
decision-makers to assess the effectiveness of health technolo-
gies, budget impact analysis is measuring the financial impact of 
the adoption and use of a new medical technology within the 
health system. This criterion is reflecting the accessibility of a new 
medical technology. Cost-effectiveness provides the basis for a 
favorable reimbursement decision, and budget impact deter-
mines what resources would be needed to actually implement this 
decision (27). Austerity makes regulators and payers more cau-
tious about the impact that a new technology would have on their 
limited budget. With regard to orphan drugs, decision-makers 
fear that the costs would be significant and may cause changes 
in resource allocation. And this is what happens in practice, as 
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health technologies with a high budget impact are much more 
likely to be rejected for reimbursement or to be subject of access 
restrictions (28).
Our study proved that strength of evidence may be a key 
criterion in MCDA. This was the top public health considera-
tion, firmly supported by all stakeholders. Evidence is not only 
used to support reimbursement decision-making but also to lend 
legitimacy to policies pursued (29). Interpretation of evidence in 
decision-making is, however, influenced by several factors, such 
as organizational support, credibility, relevance, and applicability 
in practice, political support, and legislative constraints. Scarce or 
incomplete evidence definitely increases uncertainty around deci-
sions. This could actually put new technologies at disadvantage in 
MCDA and reimbursement decisions (3). Our study showed that 
stakeholders are aware of the impact of rarity on orphan drugs’ 
evidence. They gave equal weight to cross-sectional studies, case 
reports, and expert opinions. The last two could partially replace 
clinical evidence at the initial stages of access. Nevertheless, all 
but industry representatives stressed the need for real-world data 
during the focus group discussion. In fact, national health systems 
have been increasingly looking into new coverage approaches to 
balance the need to provide adequate access to orphan drugs with 
the requirements to tackle uncertainty and obtain best value for 
money. Patient registries and risk-sharing agreements have been 
pointed out in particular for their potential with regard to this 
problem (30).
Feasibility of McDa criteria  
in assessment and appraisal  
of Orphan Drugs
The fact that there are already several published studies exploring 
MCDA implementation in assessment and appraisal of orphan 
drugs suggests that this could be the most suitable approach 
for pricing and reimbursement for these medicinal products 
and innovative therapies in general. Back in 2013, Sussex et al. 
did one of the very first MCDA pilot studies for valuing orphan 
medicines. This particular model included eight non-monetary 
criteria – four concerning the disease being treated and four 
the treatment itself, with overall weights almost equally split 
between those two categories. Authors recommended developing 
such models for use by payers and HTA bodies (10). The most 
recent study of MCDA on orphan drugs was published in 2016 
by Kolasa et al. An MCDA model was constructed, and assess-
ment outcomes were compared with real-world reimbursement 
decisions in Polish context. Different results to the standard HTA 
process were detected. Authors suggested that further scrutiny 
of an orphan drug may increase the odds of a negative decision. 
Nevertheless, inclusion of more criteria was strongly supported 
(11). Extensive methodology analyses and systematic reviews 
have additionally supported this idea (12, 16, 17).
Determining a threshold for a positive reimbursement recom-
mendation was one of the main tasks for our pilot model. While 
some authors recommend using MCDA estimates as a guide to 
decision-making rather than as a formula (3, 7), we believe that 
formalization of assessment and appraisal is a legitimate process, 
leading to balance and agreement among different stakeholders’ 
competing interests. Any negative decision is more acceptable 
whenever it is a result from a transparent and consistent frame-
work (9). The study of Kolasa et al. considered MCDA outcome 
positive if more than 50% of the maximum number of points 
was reached. Otherwise, a negative result was assumed (11). 
Our focus group discussion yielded a rather different scenario 
(Table  3). Stakeholders consensually agreed on 70 or more 
points (corresponding to 70% at least from our value model) 
as a threshold for a positive recommendation. This may be 
significantly higher than the case of Kolasa et al. However, the 
only reasonable way to accept a higher valuation of orphan drug 
benefits is if these are demonstrated clearly and unequivocally 
(15). This strict threshold ensures that only orphan therapies with 
proven value for money profile are subject to reimbursement with 
public funds. This consideration was specifically outlined by the 
health authority representatives in our focus group discussion. 
They stressed on the overall sustainability of health-care system 
and reimbursement policy.
Our study participants agreed on a conditional reimbursement 
for a health technology rated between 50 and 70 points (Table 3). 
This is very much in line with the ongoing trend in reimbursement 
frameworks to link payment to results. In the context of fiscal 
austerity, timely access to innovative therapies has to be balanced 
against priorities and resources of the health system (30, 31). 
Risk-sharing agreements are built upon several factors, includ-
ing balance between benefits and harms, certainty of evidence, 
resource considerations, values, and preferences. They represent 
performance-based reimbursement schemes, in which the price, 
level, or nature of reimbursement are tied to future performance 
measures of clinical or intermediate endpoints ultimately related 
to patient quality or quantity of life (32). Generation of new 
evidence is a key part of risk-sharing agreements, as real-world 
data on the therapy’s performance subsequently assist in making 
informed decisions on access. Patients and health profession-
als did endorse such option as a legitimate way to address rare 
disease patients’ unmet health needs.
Availability of alternative therapy (the alternative criterion) 
was an important moment in the two piloted hypothetical case 
studies. By legal definition in the EU, a medicinal product is 
orphan designated if (a) it is indicated in a rare condition, or it is 
indicated in a life-threatening, seriously debilitating, or serious 
and chronic condition, and that without incentives, it is unlikely 
that the marketing of the medicinal product would generate 
sufficient return to justify the necessary investment and (b) that 
there exists no satisfactory method of diagnosis, prevention, or 
treatment of the condition in question that has been authorized 
or, if such method exists, that the medicinal product will be of 
significant benefit to those affected by that condition (33). Patient 
representatives regarded this last part of the EU designation 
criteria for orphan drugs as a legal proof that these therapies had 
no alternatives. One patient participant even argued that there 
should be an automatic positive reimbursement recommenda-
tion in case of absence of therapeutic alternative. The choice or 
the lack of clinical comparator has been a contentious point in 
assessment and appraisal of orphan drugs (15). The decision here 
should be evidence-based, taking into account current clinical 
guidelines and unmet health needs.
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limitations
Our study results should be considered in light of their limita-
tions. We applied a simple linear additive approach to construct 
our MCDA value measurement model. It is acknowledged that 
there are more sophisticated methodologies, especially regarding 
weight and score elicitation (5, 12). Nevertheless, they pose a high 
degree of complexity and a significant cognitive burden for the 
participants. In discrete choice experiment studies that are very 
often recommenced in MCDA, the number of criteria and their 
levels are an important issue (7). This is why we opted for a sim-
ple, straightforward framework that allows for a comprehensive 
collection and analysis of preferences of various stakeholders on 
multiple criteria. Our approach is believed to be consistent with 
the way people usually made decision aggregations (11).
Selection of criteria is an important step in building an MCDA 
model. General MCDA methodology calls for completeness, 
non-redundancy, and mutual independence of decision criteria 
used (5). Our model does not fulfill the last of those requirements. 
Preferential independence means that decisions can be made by 
using a subset of criteria if the other criteria are the same for all 
alternatives irrespective of their actual values. That is, decisions 
can be made by using only the criteria on which the alterna-
tives differ (5). From a practical point of view, this particular 
requirement is not feasible in health policy and health-care set-
tings. These decisions are complex and need to balance various, 
sometimes conflicting, points of view. This is why we took and 
followed the preferences of Bulgarian stakeholders on the set of 
criteria for reimbursement decision-making. The incorporation 
of those opinions had definitely improved the external validity of 
our MCDA model.
Finally, our study was designed to address the Bulgarian 
health-care context. Preferences for weights and scores are 
country specific, as local resources, needs, and expectations 
strongly differ from one national health system to another. These 
differences impact the level of importance of individual criteria, 
making any value measurement model unique for its own public 
health settings (4). Nevertheless, our relative big sample could 
provide important insights for health policy stakeholders from 
various countries, as today all health-care systems face a common 
challenge – to balance limited budgets and increased expecta-
tions, formal requirements, and informal constraints (34, 35).
cOnclUsiOn
Progress in medicine puts methodological pressure on HTA 
application in reimbursement decision-making. Standard HTA 
paradigm poses limitations regarding integration of the diversity 
of stakeholders’ perspectives. Conventional health economic 
tools do not allow responding to those concerns. MCDA could 
successfully address this challenge, as it provides a structured, 
transparent approach to identify preferred alternatives by means 
of combined calculation of the relative importance of different 
criteria and the performance of the alternatives on these criteria. 
MCDA framework enables the exploration of stakeholders’ 
preferences, as well as the explicit organization of broad range of 
criteria on which real-world reimbursement decisions are based.
Multi-criteria decision analysis potential is significant in 
the case of innovative health technologies and orphan drugs in 
particular. Assessment and appraisal of these medicinal products 
tend to be one of the most complicated and conflicting HTA 
tasks. This is why improved knowledge on MCDA feasibility and 
integration with HTA is of paramount importance, as the drive 
for innovation in medicine should match patient needs, health-
care system resources, and societal values. Our study did create an 
MCDA value measurement model to assess and appraise orphan 
drugs in Bulgarian context, by exploring preferences on decision 
criteria’s weights and performance scores through a stakeholder-
representative survey and piloting the model through a focus 
group discussion.
Decision criteria that describe the health technology’s 
characteristics were found to be the most important group of 
considerations in reimbursement decisions, making almost half 
of the total value estimate. This outcome, combined with the high 
individual weights of disease severity and disease burden criteria, 
underlined assessment, and appraisal of innovative therapies for 
rare diseases should be put in the context of the targeted condi-
tion. This conclusion was indirectly confirmed by the low weights 
of economic criteria. Our study proved that strength of evidence 
may be a key criterion in MCDA for orphan drugs. Scarce or 
incomplete evidence definitely increases uncertainty around 
decisions. So, patient registries and risk-sharing agreements are 
among the possible options to address this problem.
Despite the fact that preferences for weights and performance 
scores are country specific, our study’s relative big sample could 
provide important insights for health policy stakeholders from 
various countries. Today, all health-care systems face a common 
challenge – to balance limited budgets and increased expecta-
tions, formal requirements, and informal constraints.
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